Skip to content

Study · Randomized controlled trial · n = 192 · 1997

5 results

Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group.

Agarwal SK, Hamrang C, Henzl MR, Judd HL

The Journal of reproductive medicine1 Jul 1997Cited by 26 (Europe PMC)

PMID9252932 (opens in a new tab)PepBankPUB-09252932
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, nafarelin and leuprolide depot were equally effective for symptoms and signs.

    In plain wordsNafarelin and leuprolide depot relieved endometriosis symptoms and signs equally.

    Peptide
    Nafarelin
    Outcome
    No significant changeEndometriosis symptoms and signs
    Study

    n = 192

    Comparator
    Leuprolide acetate depot
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Nafarelin was as effective as LA depot in alleviating symptoms and signs of endometriosis.
    2 context sentences
    Summary · context
    A multicenter, prospective, randomized, double-placebo, double-blind study was conducted on subjects who had symptoms and signs of endometriosis and bone mineral density (BMD) within the age-appropriate normal range.
    Summary · context
    For 6 months, 99 subjects received nafarelin, 200 micrograms twice daily, and placebo injections once monthly; 93 subjects received LA depot injections, 3.75 mg once monthly, and placebo nasal spray, twice daily.
  2. 02HumanRandomized controlled trialSafety outcome

    In women with endometriosis, nafarelin caused significantly less bone mineral density loss than leuprolide depot.

    In plain wordsBone density loss was lower with nafarelin than leuprolide depot.

    Peptide
    Nafarelin
    Outcome
    DecreaseBone mineral density loss
    Study

    n = 192

    Comparator
    Leuprolide acetate depot
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    LA depot recipients lost significantly more BMD, had more days with subjective hot flushes and more objectively measured hot flushes than did nafarelin recipients.
    2 context sentences
    Summary · context
    A multicenter, prospective, randomized, double-placebo, double-blind study was conducted on subjects who had symptoms and signs of endometriosis and bone mineral density (BMD) within the age-appropriate normal range.
    Summary · context
    For 6 months, 99 subjects received nafarelin, 200 micrograms twice daily, and placebo injections once monthly; 93 subjects received LA depot injections, 3.75 mg once monthly, and placebo nasal spray, twice daily.
  3. 03HumanRandomized controlled trialSafety outcome

    In women with endometriosis, nafarelin recipients had fewer days with subjective hot flushes than leuprolide depot recipients.

    In plain wordsWomen receiving nafarelin had fewer days with reported hot flushes than women receiving leuprolide depot.

    Peptide
    Nafarelin
    Outcome
    DecreaseDays with subjective hot flushes
    Study

    n = 192

    Comparator
    Leuprolide acetate depot
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    LA depot recipients lost significantly more BMD, had more days with subjective hot flushes and more objectively measured hot flushes than did nafarelin recipients.
    2 context sentences
    Summary · context
    A multicenter, prospective, randomized, double-placebo, double-blind study was conducted on subjects who had symptoms and signs of endometriosis and bone mineral density (BMD) within the age-appropriate normal range.
    Summary · context
    For 6 months, 99 subjects received nafarelin, 200 micrograms twice daily, and placebo injections once monthly; 93 subjects received LA depot injections, 3.75 mg once monthly, and placebo nasal spray, twice daily.
  4. 04HumanRandomized controlled trialSafety outcome

    In women with endometriosis, nafarelin recipients had fewer objectively measured hot flushes than leuprolide depot recipients.

    In plain wordsMeasured hot flushes were fewer with nafarelin than leuprolide depot.

    Peptide
    Nafarelin
    Outcome
    DecreaseObjectively measured hot flushes
    Study

    n = 192

    Comparator
    Leuprolide acetate depot
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    LA depot recipients lost significantly more BMD, had more days with subjective hot flushes and more objectively measured hot flushes than did nafarelin recipients.
    2 context sentences
    Summary · context
    A multicenter, prospective, randomized, double-placebo, double-blind study was conducted on subjects who had symptoms and signs of endometriosis and bone mineral density (BMD) within the age-appropriate normal range.
    Summary · context
    For 6 months, 99 subjects received nafarelin, 200 micrograms twice daily, and placebo injections once monthly; 93 subjects received LA depot injections, 3.75 mg once monthly, and placebo nasal spray, twice daily.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, estradiol was consistently higher with nafarelin than leuprolide depot, with significant differences by month 3.

    In plain wordsEstradiol was higher with nafarelin than leuprolide depot, with significant differences by month 3.

    Peptide
    Nafarelin
    Outcome
    IncreaseCirculating estradiol
    Study

    n = 192

    Comparator
    Leuprolide acetate depot
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    In the nafarelin group, estradiol levels were consistently higher than in the leuprolide depot group, with significant differences by month 3 of dosing.
    2 context sentences
    Summary · context
    A multicenter, prospective, randomized, double-placebo, double-blind study was conducted on subjects who had symptoms and signs of endometriosis and bone mineral density (BMD) within the age-appropriate normal range.
    Summary · context
    For 6 months, 99 subjects received nafarelin, 200 micrograms twice daily, and placebo injections once monthly; 93 subjects received LA depot injections, 3.75 mg once monthly, and placebo nasal spray, twice daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.